ClinicalTrials.Veeva

Find clinical trials for Chronic Lymphocytic Leukemia in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Mantle-Cell Lymphoma
Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia trials near New York, NY, USA:

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAJIC)

A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic ...

Enrolling
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Drug: Obinutuzumab
Drug: Venetoclax

Phase 3

AstraZeneca
AstraZeneca

New York, New York, United States and 42 other locations

patients with mantle cell lymphoma (MCL) and adult patients with chronic lymphocytic leukemia (CLL) who have received at l...

Enrolling
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Drug: Pembrolizumab
Drug: Ibrutinib

Phase 1, Phase 2

Joshua Brody

New York, New York, United States

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...

Enrolling
Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
Drug: Obinutuzumab

Phase 2

AbbVie
AbbVie

Hackensack, New Jersey, United States and 47 other locations

The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of t...

Enrolling
Small Lymphocytic Leukemia (SLL)
Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
Drug: Obinutuzumab

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

New York, New York, United States and 7 other locations

This study will help researchers collect more information about how effective the combination of venetoclax and obinutuzumab is in treating CLL in pe...

Enrolling
Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
Drug: Obinutuzumab

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

New York, New York, United States and 7 other locations

This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic le...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

New York, New York, United States and 11 other locations

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...

Enrolling
Small Lymphocytic Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Venetoclax
Drug: Ibrutinib

Phase 2

Janssen
Janssen

Flemington, New Jersey, United States and 15 other locations

together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Esca...

Active, not recruiting
Chronic Lymphocytic Leukemia
Lymphoma, Non-Hodgkin
Drug: JNJ-67856633
Drug: JNJ-64264681

Phase 1

Janssen
Janssen

Stony Brook, New York, United States and 27 other locations

The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D[s]) in B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic...

Active, not recruiting
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Non-Hodgkin
Drug: JNJ-64264681

Phase 1

Janssen
Janssen

New York, New York, United States and 14 other locations

This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic...

Active, not recruiting
Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
Drug: Acalabrutinib

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Stamford, Connecticut, United States and 3 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems